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Abstract
Tuberculosis is the leading cause of death by single infectious disease worldwide; novel
antibiotics are needed to continue to treat this disease. To goal of this project is to provide
proof-of-principle support for the idea that targeting protein-protein interactions (PPI) is
an appropriate course for the discovery of new drugs. This study optimized the M-PFC
assay, which allows detection of PPI in Mycobacteria, through the use of stronger
promoters and inducible expression of a peptide blocker by riboswitch. To accomplish
this, promoter induction studies were used to find stronger promoters for the M-PFC,
optimization of the riboswitch as a method for inducible protein expression within this
system, and the addition of both elements to the existing version of the M-PFC. This M-PFC
targets DosR homodimerization; this process is known to be essential for survival within
the host. This study optimizes a system that may be used to screen for drugs that are
capable of interrupting this interaction.
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Introduction
Tuberculosis (TB) disease is the leading cause of death caused by a single infectious
agent worldwide. The organism responsible for this disease, Mycobacterium tuberculosis, is
estimated to infect one third of the world’s population, through either latent or active
infection [1]. TB disease is responsible for approximately 2 million deaths annually, and 10
million new infections occur each year [2]. Tuberculosis is a disease that primarily affects
the lungs and respiratory tissues; however, other organ systems may be affected; these
organs include the liver, spleen, and bones, as well as neurological tissues and urogenital
tissues. TB is difficult to treat due primarily to poor accessibility to drugs inside of
granulomas, the persistence of dormant bacteria, and inducible drug resistance
mechanisms including efflux pumps [1]. Treatment commonly requires a cocktail of
isoniazid, rifampin, ethambutol, and pyrazinamide over the course of 6 to 9 months [1].
TB is becoming increasingly difficult to treat; drug resistant Mtb, multi-drug
resistant Mtb (MDR-TB) even extremely multi-drug resistant Mtb (XDR-TB), are an
increasing threat globally [3]. MDR-TB is defined as a TB infection that is resistant to both
isoniazid and rifampicin, and XDR-TB is resistant to isoniazid, rifampicin, and
fluoroquinolone [3]. In 2012, the World Health Organization estimated 450,000 cases of
MDR-TB worldwide, with an average of 9.6% of MDR cases being XDR-TB [3]. MDR-TB and
XDR-TB are emerging due to inadequate management of cases; patient non-compliance is
often an issue due to the length of treatment and side effects of available drugs [4].
Improper management of HIV/TB co-infection is also a possible complication to proper
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treatment [4]. Because TB is difficult to treat and becoming increasingly drug-resistant,
novel therapeutic agents are needed to treat this disease. Before the antibiotic era, TB
disease carried a mortality rate of 50% [3]. With drugs available today, the mortality rate is
17.3% [1]. The development of new drugs is important, then, to ensure we are able to
continue to treat TB disease.
Current antibiotics target several cellular processes. Isoniazid targets the synthesis
of lipids that are essential components of the cell wall [5]. Rifampicin targets core subunits
of RNA polymerase [6]. Fluoroquinolones target topoisomerases and gyrases, inhibiting
DNA replication in the pathogen [7]. As resistance to these drugs becomes more prevalent,
new targets must be sought.
Commonly used drug discovery methods mostly fall into two categories. Phenotypic
screens use a non-targeted approach; drugs are introduced to cells in media, and loss of
viability is used to study effectiveness of drugs. This method is limited because conditions
in culture are unlike conditions experienced within the host. The other approach is target
based screening, in which drugs are screened in a biochemical assay for their ability to
disrupt the function of essential targets in the cell. This approach is limited, because the
target must first be identified. Additionally, because these screens are often conducted in
silico or on purified target proteins, membrane permeability of drugs is also a concern. To
limit these concerns, new screening methods have been developed. One such screening tool
was developed by Russell et al. using a cell-based phenotypic approach in which cells were
subject to high-throughput screening while exposed to the conditions of a macrophage
phagosome [8]. Such screens mitigate limitations of traditional phenotypic screening,
2

which occurs in culture under conditions that are not necessarily similar to conditions
during infection.
The approach to drug screening used in this study is a hybrid approach to drug
screening. The Mycobacterial Protein Fragment Complementation (M-PFC) assay is a cellbased screening tool that uses a target-based approach. In this system, protein interactions
may be selectively targeted. The assay is conducted in cells, avoiding limitations of a
traditional target based approach that is conducted outside of a cell. For these reasons, the
use of the M-PFC is a novel method to study and target important protein-protein
interactions in Mycobacterium tuberculosis.
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Background
Protein-Protein Interactions
Inhibition of protein-protein interaction is a promising area for discovery of new
drugs. This approach has been validated in other studies, and allows for high-throughput
screening of a selective target [9]. Another possibility for targeting essential proteinprotein interactions is the use of proteomimetics to create small molecules that mimic the
structure of the interaction interface, allowing competitive inhibition of the interaction
[10]. A screen for proteomimetic inhibitors of p53/hDM2 and other PPIs involved in cancer
pathogenesis revealed that proteomimetic compounds could inhibit these interactions and
show promise for use as anticancer agents [10].
By blocking such interactions in pathogenic organisms, bacteria can be inhibited
through a targeted and specific pathway. The M-PFC (Mycobacterial protein fragment
complementation) assay is commonly used to study protein-protein interactions (PPI) in
Mtb and other mycobacteria. By preventing the interaction of proteins such as essential
regulators, a drug could be discovered to selectively inhibit Mtb specifically, resulting in
decreased pathogenesis and death of Mtb. This project focuses on specific Mtb proteinprotein interactions thought to be important for virulence and viability. One such regulator,
DosR, is part of a two-component system, which regulates an essential dormancy regulon
of approximately 50 genes. It forms a homodimer that is essential for Mtb survival under
hypoxic conditions, which occur during infection within the host. A drug capable of
blocking this interaction would result in decreased viability.
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Figure 1: M-PFC Mechanism

The M-PFC system was developed by Steyn et al. to study and quantify proteinprotein interactions in vivo in Mycobacteria [11]. This system utilizes Mycobacterium
smegmatis as a model organism; this is ideal for drug screening, because it is closely related
to Mtb but is considered to be safe and non-pathogenic; M. smegmatis can be grown outside
of a BSL-3 facility and additionally grows faster than Mtb. The mycobacterial cell wall can
present difficulty for the antibiotic permeability, and M. smegmatis is similar in structure
[11]. For these reasons, M. smegmatis is an ideal model organism. In the M-PFC system,
proteins of interest are linked to domains of a split dihydrofolate reductase (DHFR)
protein. When the two proteins interact, the domains of DHFR are brought into close
enough proximity to interact, recreating the active site of the protein and enabling survival
5

on trimethoprim (TRIM) proportional to the strength and quantity of the protein
interaction. Figure 1 illustrates the mechanism through which proteins interact, bringing
DHFR domains into contact. The system is similar to the Yeast Two Hybrid assay; however,
it has been adapted for use in mycobacteria. Post-translational modifications of bacterial
proteins are not always appropriate in yeast, and the high GC content of Mycobacteria DNA
is not always well tolerated in yeast [11]. Although the assay is traditionally used to
quantify the strength of an interaction between two proteins, it may be used to study a
disruption of normal interactions between two proteins [6]. Once protein interactions are
quantified with the M-PFC, a disruption to the interaction can be identified using the M-PFC
as a tool for high throughput screening. This assay allows a hybrid approach to drug
screening, in which an interaction may be targeted within a whole cell screen [12]. The MPFC system uses two plasmids, pUAB100 and pUAB200 [11, 12]. Each plasmid expresses
one protein of interest linked to one half of a split DHFR. pUAB100 is an episomal plasmid,
while pUAB200 lacks OriM, the mycobacterial origin of replication, and is incorporated into
the host chromosome [11].
The M-PFC system is limited as a drug-screening tool in certain areas. Certain
analogs of sulfa drugs act on tetrahydrofolic acid synthesis and interfere with the DHFR
component of the assay; these drugs cannot reliably be screened using the M-PFC system
[12]. Another possible limitation arises from solubility of drugs. To avoid solubility issues,
drugs may be used in 10% DMSO in the M-PFC assay[12]. Another limitation of this method
is that the interaction interface must be small enough to be disrupted by a small molecule;
the molecule must be able to enter the cell and block the interaction [12]. The interaction
6

must also not be too robust to be effectively blocked in vivo. Another important caveat of
this method is the need to identify and verify an essential PPI in advance; the use of a
riboswitch inducible blocker to address this requirement is introduced in this study.
Protein Interaction Target: DosR Homodimerization
DosR, also known as DevR, is involved in the hypoxia response of Mycobacterium
tuberculosis. DosR expression is induced in response to low oxygen tension, nitric oxide,
carbon monoxide, and citric acid [13]. These conditions are experienced during Mtb
infection; bacteria react to hypoxic conditions they encounter within the phagolysosomes
macrophages and within granulomas [13]. It is part of the atypical tripartite DosRST two
component system. DosS and DosT are histidine kinases that respond to hypoxic conditions
by phosphorylating DosR, leading to dimerization. Under such conditions, it forms a
homodimer that is involved in the regulation of 48 genes thought to contribute to Mtb’s
ability to survive under hypoxic conditions encountered during infection. DosR was chosen
as a target for this project because it is essential under hypoxic conditions and its role is
well documented in literature [14-16]. Preventing DosR-DosR homodimerization would
decrease expression of genes that allow Mtb to survive in low oxygen environments,
decreasing cell viability in response to in vivo stresses [16]. In DosR knockouts, DosR has
been seen to be essential for survival under hypoxic conditions [14, 15]. In macaque
models, DosR knockout mutants showed significant attenuation after initial infection;
under hypoxic conditions, attenuation allowed for the elimination of Mtb [16]. For this
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reason, an agent capable of selectively disrupting this interaction would be effective for
treating an active or dormant Mtb infection [15].
Riboswitch
The riboswitch is optimized in this study as an addition to the M-PFC assay. It is a
genetic, mRNA construct that allows for inducible expression of a protein. Adding the
riboswitch to the M-PFC system allows for the expression of proteins/peptides that will act
as competitive inhibitors to disrupt protein interactions in the M-PFC assay. This system
can be used to validate competitive inhibitors; once validated, the system can be used to
truncate proteins and determine the dimerization domain. Then, riboswitch:inhibitor
constructs may be introduced into M. bovis BCG or Mtb and expressed to study effects of
blocking interactions in culture.
Figure 2: Simplified Illustration of Riboswitch Mechanism
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The riboswitch system of controlling protein induction at the translational level is a
new addition to the M-PFC system. A riboswitch is a sequence at the start of an mRNA that
forms a hairpin structure. Figure 2 shows a simplified diagram of the riboswitch
mechanism used in this study. Depending on the system, the addition of an inducer will
bind to the aptamer region of the RNA hairpin altering its structure to either expose or
obstruct the ribosome-binding site (RBS). A synthetic riboswitch for use in Mycobacteria
has been identified and developed by Seeliger et al. [8]. In this system, a riboswitch forms a
secondary structure that obstructs the RBS. Theophylline, the inducer, binds the aptamer,
leading to a conformational change that exposes the RBS, allowing translation to occur. The
level of protein induction is proportional to the concentration of the inducer. For this
reason, the system can be used to control the level of protein induction within a system [8].
A DosR-DosR M-PFC expressing a riboswitch-truncated DosR construct will be created in
Mycobacterium smegmatis to observe the competitive inhibition of the interaction. After
this approach is validated, in future work, the riboswitch-controlled DosR fragment will be
expressed in Mtb surrogate M. bovis (BCG) to demonstrate proof of principle for this as a
new potential drug target through decreased expression of downstream genes by qRT-PCR
or by impaired survival under hypoxia.
A high throughput drug screen using the M-PFC and DosR as a target was conducted
as a collaboration between Dr. Rohde and Sanford Burnham Prebys Medical Discovery
Institute through the Florida Translational Research Program. This screen utilized the
hsp60 version of the assay rather than the updated assay in this study. In this study,
433,014 compounds were screened for their ability to inhibit DosR:DosR
9

homodimerization in the DosR:DosR M-PFC strain. Of these compounds, 1,072 revealed
activity of greater than 30%. Through counter screening, 206 compounds were found to
target DosR specifically rather than other essential cellular processes. This was indicated
through survival in the absence of TRIM. 83 of these compounds were selected for their
structure as promising targets, and future testing will be conducted on these compounds.
This area of drug discovery is promising because it allows for the screening and
identification of novel compounds; in the future, more M-PFC strains will be created.
Optimization will improve our ability to screen compounds in this way, and will hopefully
lead to the discovery of novel therapeutic agents for the elimination of Mtb.

10

Objectives
The proposed objectives for this project are:
1. To optimize the M-PFC system for greater protein induction through the use of
stronger promoters, increasing signal to background detection.
2. To demonstrate riboswitch inducible competitive inhibition of protein targets by
development and optimization of an M-PFC DosR screening strain with the addition
of a riboswitch-inducible protein.
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Methods
Fastcloning
M-PFC strains and other constructs were created using Fastcloning [17]. Fastcloning
is a method that allows cloning without the use of restriction enzymes or ligases; this
method uses overhanging primers to insert a gene of interest at any site in a plasmid.
Primers with overhanging nucleotides that are reverse complements of the ends of the
plasmid into which the insert gene will be placed were used to create insert DNA fragments
through polymerase chain reaction (PCR). PCR reactions used 0.25 μL (1 unit) Phusion
polymerase, 0.2 mM dNTPs, 0.6 μg/μL template DNA, 0.2 μg/μL forward primer, 0.2 μg/μL
reverse primer, 5 μL 1x GC buffer, and 16.5 μL deionized water. PCR conditions are as
follows:
Table 1: PCR Reaction Cycle Procedure

Cycle
Initial Melting
Melting
Annealing
Extension
Final Extension

Time (s)
30
10
30
15/kilobase of
DNA to be
replicated
180

Temperature (°C)
98
98
65

Repeats
1x
18x

72
72

1x

Amplification of the vector was conducted with divergent primer pairs that define
the site of insertion. Vector and insert DNA were combined and subjected to Dpn1
digestion for 1 hour, to digest methylated DNA including unamplified original plasmid DNA.
Then, 2 μt of this mixture was introduced to chemically competent E. coli and heat shocked
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for 30 seconds before 200 μn of SOC media was added. Cells were then shaken at 37°C
for 1 hour before plating on appropriate antibiotic. To allow for selection for colonies
containing the plasmid of interest, plasmids contain antibiotic selection makers. For
plasmids used in this study, pST5552, pVVRG, and pUAB200 base plasmids contain a region
that confers kanamycin resistance, and pUAB100 base plasmid contains hygromycin
resistance. Strains were plated on appropriate antibiotics after transformation, and PCR
was used to confirm the presence of the gene of interest. pUAB200, pST5552, and pVVRG in
E. coli were plated on LB agar with 50μg/ml kanamycin (K50), and pUAB100 in E. coli was
plated on LB agar with 250μg/ml hygromycin (LB H250). Colony PCR was performed using
primers flanking the region of insertion. Cells are picked from each colony with a sterile
toothpick and boiled for 5 minutes in 20 μL of sterile, deionized water. The lysate is used as
a PCR template, and PCR band size is used to confirm the presence of an appropriately
sized band. Once confirmed with PCR, plasmid DNA was purified and sent for sequencing
by Eurofins.
Promoter Induction Assay
Stronger promoters were sought to improve expression of protein partners to
enhance the signal to background ratios in the M-PFC assay. Hsp60 is a commonly used
promoter in mycobacteria, and is the promoter that drives expression of protein partners
in the M-PFC as well as in the pST5552 plasmid. To find new promoters, microarray data
obtained by Dr. Rohde was analyzed to find promoters of consistently high activity.
Promoters of Rv1197, Rv1038, and cspA were chosen as strong promoters with
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constitutive expression levels and were cloned in front of GFP in the PVVRG plasmid
(Figure 3). The activity of these promoters was compared to the activity the smyc promoter
based on levels of GFP fluorescence. For this assay, the PVVRG plasmids containing
promoter:GFP constructs were electroporated into M. smegmatis competent cells.
Transformed cells were plated on LB agar with 25 μg/ml kanamycin (K25), then selected
colonies were grown up in 5 mL of 7H9 media with kanamycin for selection. Cells of OD 0.2
were incubated in a 96 well plate, 100 μL total volume. GFP and mCherry induction were
measured by fluorescence in a Synergy H4 plate reader.
Riboswitch
Riboswitch plasmid pST5552 was obtained from Seeliger et al [18]. The plasmid
contains a riboswitch-inducible GFP driven by the hsp60 promoter. See Appendix A, Figure
S1 for features of the riboswitch plasmid construct. This plasmid was introduced into
Mycobacterium smegmatis (Msm) through electroporation. 200-500 μg of DNA was added
to 100 μL of Msm competent cells, which were electroporated, added to 250 μL of LB
Tween 0.05%, and shaken for 4 hours before being plated on LB Kanamycin 25 μg/mL. A 6
hour assay was conducted where 100 μL total volume with cells of OD 0.1 and 0.2 were
incubated for 6 hours with theophylline concentrations of 0, 0.25, 0.5, 1, 2, 4, 6, and 8 mM.
To achieve these concentrations, a 10 mM theophylline stock was diluted; this stock was
made using sonication to increase solubility of theophylline. The plate was read at an
excitation of 485 nm and emission at 528 nm for GFP fluorescence after 6 hours.
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To understand differences between maximum expression under the riboswitch
system and under standard expression under the control of a promoter alone, an assay was
conducted to compare GFP expression under each system. Msm strains containing PVVRG
and pST5552 were compared for GFP induction. PVVRG contains hsp60::GFP, and pST5552
contains hsp60::riboswitch:GFP, allowing for comparison of the system with and without
the riboswitch. This assay was conducted in a 96-well black bottom plate with 100 μL total
volume with cells of OD 0.1. The cells were incubated for 6 hours with theophylline
concentrations of 0, 0.25, 0.5, 1, 2, 4, 6, and 8 mM theophylline and 7H9 media. After 6
hours, the plate was read at an excitation of 485 nm and emission at 528 nm.

Optimizing Riboswitch for M-PFC
To optimize this assay for the M-PFC assay, a 48-hour assay, we sought to determine
optimal lower concentrations of theophylline. Msm containing either pST5552 (original
plasmid containing hsp60::Riboswitch:GFP), pST5552smyc (smyc::Riboswitch:GFP), and
PVVRG (a control containing hsp60::GFP) were added to each well of a 96-well plate. The
plate was read at an excitation of 485 nm and emission at 528 nm for GFP fluorescence
after 6 hours. This experiment was adapted from a study by Seeliger et al, and a similar
study was conducted to optimize theophylline levels for the 48 hour M-PFC assay.
Concentrations of 2, 1, 0.5, 0.25, 0.125, and 0 mM of theophylline were created in each well
using a serial dilution from a stock of 10 mM theophylline. The plate was read at an
excitation of 485 nm and an emission of 528 nm for GFP fluorescence after 48 hours. After
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optimization of theophylline levels, fastcloning was used to replace GFP with DosR, so that
the riboswitch-controlled DosR construct could be added to M-PFC strains.

Construction of M-PFC Strains
The next goal was to construct an M-PFC strain in which a riboswitch-DosR
construct was added to pUAB100. This pUAB100 features both the DosR-DHFR construct
and the riboswitch-DosR construct, which is expected to competitively inhibit the
interaction between the two DosR-DHFR halves. Positive clones are confirmed through PCR
screening and through sequencing. Using fast cloning, DosR was added to the riboswitch
plasmid pST5552 downstream of the riboswitch. Positive clones were selected for using
Kanamycin resistance of the plasmid in E. coli. Positive clones are confirmed through PCR
screening and through sequencing. The riboswitch-DosR construct was then added to a
region of the pUAB100 plasmid distinct from the DosR-DHFR cassette. Both this plasmid
and pUAB200 containing the DosR-DHFR construct were introduced into Msm through
electroporation, and colonies containing both plasmids were selected for with LB K25 H50
agar plates. See Appendix A Figure S3 for illustration of M-PFC plasmid constructs.
M-PFC Alamar Blue Assay
Three cultures are used for the M-PFC assay. The positive control strain contains a
pair of M-PFC plasmids both expressing GCN4, a zinc finger domain known to undergo
strong homodimeric interactions, fused to DHFR domains. The negative control contains
pUAB100 only, which should show no signs of interaction because only one half of the
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DHFR protein is present. The test strain contains both M-PFC Plasmids pUAB100 and
pUAB200, each containing DosR linked via glycine linker to DHFR-A or DHFR-B,
respectively. 135 μL of culture at an OD 0.0005 was added to each well of a sterile black
bottom 96-well plate. 15 μL of TRIM is added to each well in decreasing concentration;
trimethoprim concentrations are prepared by serial dilution in 10% DMSO to create a
gradient from 200 μg/mL to 0 μg/mL for each strain. Wells that receive no trimethoprim
are given 15 μL of 10% DMSO instead. The plate is incubated at 37°C for 48 hours.
After 48 hours, an Alamar blue assay is used to measure cell viability. If proteins
interact in the M-PFC assay, DHFR halves will be brought together, and TRIM resistance
will result. Therefore, cells with stronger protein interactions will survive higher
concentrations of TRIM, and cell viability can be used to measure strength and presence of
protein interactions. To measure cell survival, 15 μL of 10x Resazurin is added to each well.
Resazurin is a dye used to measure cell viability; in the presence of live cells, blue resazurin
dye is reduced to pink resorufin. After addition of resazurin, the plate is incubated for 4
hours at 37°C, then read on a Synergy 4 plate reader using monochromators with an
excitation of 530 nm and an emission of 590 nm.
Conducting M-PFC of Test Strains
M-PFC strains containing DosR were previously constructed. In this project, these
strains will be optimized and updated. The first update was the addition of a
“riboswitchable” blocker DosR to the pUAB100 plasmid containing the DosR-DHFR fusion.
This updated pUAB100DosRRiboDosR was added with pUAB200DosR to M. smegmatis by
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electroporation. M-PFC Alamar blue assay was conducted with this strain. Once M-PFC
strains are assembled, the M-PFC and Alamar blue assay will be completed. Theophylline
levels were optimized for the assay using results from GFP riboswitch induction studies
described above. For early versions of this assay, theophylline levels were optimized at 4
mM based on data from the 6 hour GFP inductance assay.
Improvement of M-PFC Strains
Fastcloning was used to replace the hsp60 promoter that drove expression of DosRDHFR fusions with the smyc promoter in pUAB100 and pUAB200. The smyc promoter was
chosen as a result of the Promoter Induction Assay described above; it is a promoter taken
from Mtb that shows constitutive high expression in microarray data. The smyc promoter
was amplified from Mtb DNA, and added to pUAB100DosR and pUAB200 DosR in place of
the hsp60 promoter that controlled DosR expression. Both plasmids were introduced into
M. smegmatis through electroporation. M-PFC Alamar blue assays were conducted using
smyc:DosR M-PFC strains.
Finally, an M-PFC strain was constructed in which smyc was used to replace the
hsp60 promoter that drove expression of the riboswitch DosR construct, which was added
to pUAB100 as a riboswitch inducible competitive inhibitor. Both plasmids were
introduced into M. smegamtis through electroporation. M-PFC Alamar blue assays were
conducted using smyc:DosR M-PFC strains.
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Results
Promoter Induction and Reporter Strain Assays
The hsp60 promoter originally controlled expression of DosR – DHFR fusions on M-PFC
strains and RiboDosR. Because stronger promoters could enhance detection of weak
interactions, new promoters were sought. Promoters were identified from microarray data
of Mtb promoters. GFP reporter assay was used to assess the relative activity of promoters.
Reporter strains were created for this assay using fastcloning in the PVVRG plasmid. The
hsp60 controls GFP expression in this plasmid, and promoters of Rv1197, Rv1038, and cspA
were chosen and induction was compared to strong promoters identified from microarray
data or literature (smyc). GFP signal was normalized to fluorescence of constitutive
mCherry. Results are seen below in Figure 3. All promoters exhibited activity, and 3 of 4
exhibited greater activity than hsp60. The smyc promoter was chosen for improvement to
the assay because smyc yielded the greatest GFP fluorescence in the assay.

19

Figure 3: GFP Expression By Promoter Reporter Strain
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Riboswitch Optimization
An Msm strain containing an hsp60::riboswitch:GFP construct expressed from a plasmid
was created. A 6-hour assay was conducted where 100 μL of cells at either OD 0.1 or 0.2
were incubated for 6 hours with different theophylline concentrations. This assay
replicates an assay performed by Seeliger et al. [18]. An initial study of protein expression
under riboswitch control, this assay was updated to study theophylline concentrations for
induction over 48 hours, as required in the M-PFC alamar blue assay. See Figure 4 for the
results of this assay. Between a starting OD of 0.1 and 0.2, a significant difference in
theophylline dose-dependent induction was not observed. This study provided initial
information about the dose-dependent range of induction through the use of the riboswitch
expression system.
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Figure 4: Theophylline Induction of GFP by Riboswitch
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An assay was conducted in which GFP induction under control of the riboswitch was
compared to GFP expression under the control of a promoter alone. This assay was
conducted to determine possible expression range when compared with expression from
the same promoter without the riboswitch. In this assay, Msm containing PVVRG and
pST5552 were compared. PVVRG contains hsp60::GFP, while pST5552 contains
hsp60::Riboswitch:GFP. A 6 hour assay was conducted where 100 μL total volume with
cells of OD 0.1 were incubated for 6 hours with different theophylline concentrations in a
96-well black bottom plate with 7H9 growth media. Results are shown below in Figure 5.
The riboswitch allows for controlled protein expression; however, protein expression is
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lower under riboswitch control, and does not reach the same levels of expression as a
standard promoter expression system alone. At 4 mM theophylline, GFP fluorescence
under the riboswitch system is 64.8% of fluorescence under the hsp60 promoter alone. A
gradual decline is seen in fluorescence of the non-riboswitch strain which may be due to
the presence of increasing levels of theophylline.
Figure 5: Riboswitch Regulated Expression of Protein
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An Msm strain containing an hsp60::Riboswitch:GFP construct expressed from a
plasmid was created and compared to an Msm strain containing smyc::Riboswitch:GFP. A
48 hour assay was conducted where 100 μL total volume with cells of OD 0.2 were
incubated for 48 hours with different theophylline concentrations as seen in Figure 2. This
assay was conducted to optimize theophylline levels for the M-PFC assay, which requires a
48-hour incubation period. From this assay and the previous assays, a concentration of 4
mM theophylline was chosen for M-PFC screening. 4 mM Theophylline reaches the highest
level of expression. This assay also allows comparison between promoters hsp60 and smyc
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as promoters of the riboswitch. Results are shown below in Figure 6. Protein expression
measured through GFP fluorescence was approximately 2 times greater at all data points
with the promoter smyc.
Figure 6: hs60 and smyc Riboswitch Induction of GFP
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M-PFC and M-PFC Optimization
Results of a DosR-DosR M-PFC protein interaction study are included below in Table 2 for
baseline comparison. This data was collected by Zina Versfeld, a former undergraduate
researcher in the Rohde lab. This M-PFC was conducted using pUAB100 and pUAB200 with
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an hsp60::DosR-DHFR construct. The positive control is GCN4-GCN4, a known strong
interaction. The negative control includes only the pUAB100 plasmid with DosR-DHFR, so
no interaction should occur because both halves of DHFR are not present. In this assay, the
hsp60 promoter controls DosR expression. When replaced with smyc, DosR levels should
increase, increasing potential for interaction and increasing the signal to background ratio
as a result.
Table 2: Preliminary M-PFC Alamar Blue

Induction of DosR was predicted to block DHFR assembly by inhibiting DosR dimerization,
thus increasing TRIM sensitivity. To test this, an M-PFC was conducted using
pUAB200DosR and pUAB100DosR with the riboswitch:DosR blocker expressed on
pUAB100. As predicted, we noted RiboDosR induction in the presence of theophylline led
to increased cell death. This effect was most pronounced in the mid-range of trimethoprim
concentration, the difference in cell viability is most significant at 12.5 mM trimethoprim
and 25 mM trimethoprim. This assay was conducted to compare M-PFC strains with and
without the riboswitchable DosR blocker; results from this assay are seen in Figure 7.
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These results show proof of principle for the concept of the induction of a blocker peptide
by riboswitch as a method of validating inhibition of protein interaction. Demonstration
that expression of effective blocker peptides in M. tuberculosis leads to loss of viability or
virulence would serve to validate the chosen PPI as a drug target. Results from this assay
may also be used to optimize trimethoprim concentrations for future screens with greatest
difference between strains with and without the expressed blocker. In future studies, these
results may be used to optimize expression of truncated protein blockers, which is
ultimately the goal of the riboswitch expression system as an addition to the M-PFC.
Figure 7: Theophylline Induction of RiboDosR Sensitizes DosR:DosR M-PFC to TRIM
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An M-PFC comparing the smyc:DosR updated strain was compared to the original
hsp60:DosR strain constructed by Zina Versfeld. As seen in Table 3, the smyc strain yields
greater survival at higher levels of trimethoprim. At 3.125 mM TRIM, this difference is
particularly evident. This assay supports the idea that increasing expression of protein
partners yields a greater signal to background ratio in the M-PFC, producing more robust
results.
Table 3: M-PFC of smyc:DosR and hsp60:DosR
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Discussion
This project hopes to address the greater problems of Mtb infection and growing
antibiotic resistance by providing a novel approach to drug screening. New therapies are
needed for the treatment of tuberculosis, and the use of the M-PFC as a tool for screening
inhibitors of protein-protein interactions is a promising new area for drug discovery. This
project serves a dual purpose in this area; through the use of new promoters, the M-PFC
system can be optimized to increase expression of protein partners, reducing signal to
background ratios of the assay. GFP reporter strains were constructed to identify stronger
promoters for the M-PFC system, and the strongest promoter, smyc, was used to replace the
hsp60 promoter in the DosR-DosR M-PFC. The other addition is the use of the riboswitch as
a method of inducing protein expression at a controlled level. Through this project, three
new M-PFC strains were constructed. These include the hsp60 DosR M-PFC with the
addition of the riboswitch controlled blocker, and the smyc DosR M-PFC with and without
the riboswitch controlled blocker. The flow of this study is described in the flow chart
figure below.

27

Figure 8: Flowchart of Study Design
Optimization of
Riboswitch through
GFP induction assay

Addition of
riboswitch:DosR to
hsp60 M-PFC

Addition of smyc to
Riboswitch,
smyc::Riboswitch:GFP
Induction Study

Identification of
stronger promoters
through GFP reporter
strains

Addition of both smyc and the
smyc::Riboswitch:DosR
expression system to the MPFC

Addition of smyc to the
DosR M-PFC system

From the promoter GFP expression study, data indicated that smyc resulted in
greater protein expression over hsp60 and other Mtb promoters tested. For this reason,
smyc was chosen to replace hsp60 as the promoter driving the M-PFC and riboswitch
expression systems. By increasing induction through smyc, signal to background ratios are
seen to be decreased. In the 48-hour assay, at 1 and 2 mM of theophylline, GFP fluorescence
approximately doubles under smyc control over hsp60. This is first seen in the
pST5552smycRiboGFP constructs in Figure 6; at every concentration of theophylline in the
study, GFP fluorescence is greater under control of smyc than hsp60.
Initial results from the addition of the inducible blocker peptide to the M-PFC as
seen in Figure 7 suggest that the blocker is capable of producing a measurable interference
in the M-PFC system. This provides support for the use of the M-PFC as a drug screening
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technique. In the future, this system will be used to truncate the blocker. Truncation of the
protein will allow for the discovery of the minimal domain necessary to block the
interaction. Identifying this minimal region of the peptide will allow for the expression of
this non-functional peptide fragment in vivo to study viability and downstream effects.
Identification of this domain also opens the possibility for drug discovery through
peptidomimetic inhibition, in which a small molecule that mimics the shape of the peptide
may be designed to block the interaction. Truncated proteins will be introduced into the
M-PFC with the riboswitch, allowing the study of their ability to block the protein
interaction of interest. Once the riboswitch-truncated-protein cascade is constructed, it
may be introduced in BCG to study transcription of downstream products and survival
under hypoxia. The smyc::DosR + smyc::Riboswitch:DosR M-PFC may also now be used for
additional protein targets.
It is important to recognize possible limitations of this study. Solubility of
theophylline was, at first, a weakness. Theophylline is a crystalline solid that is difficult to
dissolve in water. Sonication of the solution for 1 hour allowed for the creation of a 10 mM
stock solution. Theophylline toxicity was a concern as well in early studies; however, with
optimization using a 48 hour induction assay, these conditions were mitigated through the
use of a lower dose. Another possible limitation is the inability of the riboswitch to
completely eliminate expression of the target protein in the absence of theophylline. In the
6-hour assay, GFP fluorescence is 318 for OD 0.1 and 382 for OD 0.2. In the 48-hour assay,
fluorescence values were 1768 for hsp60 and 1700 for smyc. Little difference between the
two promoters was seen at this lowest level of expression, however, indicating that smyc
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does not lead to greater unintended expression. This result is supported by Seeliger et al in
their use of riboswitch expression in Msm [18]. Figure 3 also illustrates the upward limits
of the riboswitch induction system. While it is important to note that the riboswitch does
not allow for expression levels that are as high as those accomplished through traditional
expression, the riboswitch system is valuable over traditional expression because protein
levels can be controlled.
For the final two assays, repeats of the study have not yet been conducted.
Repeating studies is optimal, however, time did not allow for a repeat assay. The assay is
conducted in replicate to mediate some of these limitations. In the future, more replications
will be conducted with all strains constructed as a part of this study, and future
optimization will occur.
In future work, the smyc::DosR M-PFC strains could be used for additional high
throughput screening studies. The smyc::DosR M-PFC strain will now be used to validate
hits from the Sanford Burnham Prebys DosR screen through the Florida Translational
Research Program. This screen was conducted to find inhibitors of the DosR-DosR
interaction; if inhibitors are validated, they may then be tested in vitro against BCG or Mtb.
These optimized plasmids will also be used to screen additional protein targets, allowing
for the identification of possible therapeutic agents. Greater signal to background ratios
will improve this assay by enhancing survival of bacteria where an interaction is present,
allowing for greater confidence in the identification of hits.
With high throughput screens like the screen conducted through collaboration with
the Sanford Burnham Medical Discovery Institute as well as other screens in the lab and
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future collaborations, studies like this hope to provide the tools necessary to discover novel
therapeutic agents in the interest of eradicating tuberculosis. Continued development of an
optimized screening platform for PPI inhibitors and methods to identify and validate
essential and validate essential PPIs could have a significant impact on efforts to discover
novel treatments for TB.
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Appendix A: Plasmid Maps
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Figure S1: PVVRG Plasmid
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Figure S2: pST5552 Riboswitch Plasmid
hsp60/smyc
promoter

Riboswitch

GFP

OriE

Figure S3: M-PFC DosR-DosR plasmid set with smyc promoter:
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Appendix B: Primer Table
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Table S1: Fast Cloning Primers
Primer Name
PVVRG_esat6_FC_F
PVVRG_esat6_FC_R
PVVRG_1038_FC_F
PVVRG_1038_FC_R
PVVRG_Rv1197_FC_
F
PVVRG_Rv1197_FC_
R
PVVRG_cspa_FC_F
PVVRG_cspa_FC_R
smycRibo_FC_5552F
smycRibo_FC_5552R
smycRibo_FC_5552F
smycRibo_FC_5552R
5552_pro_sub_F
5552_pro_sub_R
smycDosR_FC_100-F

Primer
CTGGATGATGGGGCGAgcaggtg
acgtcgttgttc
CCAGTGAAAAGTTCTTCTCCT
TTACTCATgctggactactttctctctt
taccttcc
CTGGATGATGGGGCGAcctagca
aatgccctgaacag
CCAGTGAAAAGTTCTTCTCCT
TTACTCATgctgctgtctccttgtctc
g
CTGGATGATGGGGCGAgatgttg
aagggctttgct
CCAGTGAAAAGTTCTTCTCCT
TTACTCATgttgcctgtctccttgttga
ac
CTGGATGATGGGGCGAtgatagg
ccaacgactttcc
CCAGTGAAAAGTTCTTCTCCT
TTACTCATttctcgatctttccttttctt
ctg
CGCGGTACCAGATCTTTAAAT
CTAGA GGATCGTCGGCACCG
TCACCGGTACCTATAGTGAGT
CGTAT
GGATCCGGATCGTGCTC
CGCGGTACCAGATCTTTAAAT
CTAGAGGATCGTCGGCACCG
TCACCGGTACCTATAGTGAGT
CGTATGGATCCGGATCGTGCT
C
ATACGACTCACTATAGGTACC
GGTGA
TCTAGATTTAAAGATCTGGTA
CCGCG
CCGCGGTACCAGATCTTTAAA
GGATCGTCGGCACCG
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Function
Forward Primer esat6 (3875)
promotor
Reverse Primer esat6 (3875)
promotor
Forward Rv1038 primer promotor
Reverse Primer Rv1038 promotor
Rv1197 Forward Primer promotor
Rv1197 Reverse Primer promotor
Rv3648c Forward Primer
promotor cspa
Rv3648c Reverse Primer promotor
cspa
To copy smycRiboDosR cascade
from pST5552 to add to
pUAB100smycDosR
To copy smycRiboDosR cascade
from pST5552 to add to
pUAB100smycDosR
F insert primer to clone smyc in
place of hsp60 driving riboS-GFP in
pST5552
R insert primer to clone smyc in
place of hsp60 driving riboS-GFP in
pST5552
F vector primer in pST5552 to
insert smyc - downstream of hsp60
R vector primer in pST5552 to
insert smyc - upstream of hsp60
F primer to insert the smyc
promoter in front of DosR in
pUAB100-mCh

smycDosR_FC_100-R ATCGACCAAGAAGACCTTTAC
CACGGATCCGGATCGTGCTC

R primer to insert the smyc
promoter in front of DosR in
pUAB100-mCh
100_FC_smycDosR-F GTGGTAAAGGTCTTCTTGGTC F vector primer for smyc promoter
GAT
in front of DosR in pUAB100-mCh
100_FC_smycDosR-R TTTAAAGATCTGGTACCGCGG R vector primer for smyc promoter
in front of DosR in pUAB100-mCh
RibosmycDosR_100_ gcaacgcgtgagcccGGATCGTCGG To copy the smycDosRRibo cascade
F
CACCG
to add to pUAB
RiboDosR_100_R
cgccatcgacggcgcgTCATGGTCC To copy the DosRRibo cascade to
ATCACCGGG
add to pUAB
RiboDosR_100_R_2
ggcgcgccgaaggccttTCATGGTC To copy the DosRRibo cascade to
CATCACCGGG
add to pUAB
pUAB100_DosR_mC AAGGCCTTCGGCGCGCC
To copy the pUAB plasmid to insert
h_Ribo_F_2
the DosRRibo cascade
smycDosR_FC_200-F CGTTCCCGCCAGAAATCTGGA F primer to insert the smyc
TCGTCGGCACCG
promoter in front of DosR in
pUAB200-mCh
smycDosR_FC_200-R CGAACAATTGTCTTGGCCAGG R primer to insert the smyc
ATCCGGATCGTGCTC
promoter in front of DosR in
pUAB200-mCh
200_FC_smycDosR-F CGAACAATTGTCTTGGCCA
F vector primer for smyc promoter
in front of DosR in pUAB200-mCh
200_FC_smycDosR-R AGATTTCTGGCGGGAACG
R vector primer for smyc promoter
in front of DosR in pUAB200-mCh
200_FC_smycDosRTGGCCAAGACAATTGTTCG
F vector primer for smyc promoter
F.2
in front of DosR in pUAB200-mCh
smycDosR_FC_200CATTGCCGTTCCCGCCAGAAA R primer to insert the smyc
F.ext
TCTGGATCGTCGGCACCG
promoter in front of DosR in
pUAB200-mCh
smycDosR_FC_200TGGCCAAGACAATTGTTCGGG R primer to insert the smyc
R.2
ATCCGGATCGTGCTC
promoter in front of DosR in
pUAB200-mCh
smycDosR_FC_200ACCACTCGAACAATTGTCTTG R primer to insert the smyc
R.ext
GCCAGGATCCGGATCGTGCTC promoter in front of DosR in
pUAB200-mCh
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Table S2: Sequencing and Screening Primers
Primer Name
Primer
pUAB100_smyc_screen_F
CCGCGGTACCAGATCTT
TAA
pUAB100_smyc_screen_R
TCGACCAAGAAGACCTT
TACCA
pUAB200_smyc_screen_F
CGTTCCCGCCAGAAATC
T
pUAB200_smyc_screen_R
CGAACAATTGTCTTGGC
CA
pST5552_smyc_screen_F
CGCGGTACCAGATCTTT
AAATCTAGAG
pST5552_smyc_screen_R
TCACCGGTACCTATAGT
GAGTCGTAT
smycDosRscreen_200
CCGGATCCGTGGTAAAG
G
smycDosRscreen_100
CGGATCCTGGCCAAGAC
smyc_seq100_F
smyc_seq200_F
smyc_seq5552_F
smyc_screen_F
GFPProSeq-F
GFPProSeq-R
smyc_screen_F
pUAB200smycSeqF
pUAB200smycSeqR
pST5552ProRiboSeqF

Function
To screen pUAB100DosR for
smyc
To screen pUAB100DosR for
smyc
To screen pUAB200DosR for
smyc
To screen pUAB200DosR for
smyc
To screen pST5552 for smyc
To screen pST5552 for smyc

To sequence for the
smyc DosR overlap
To sequence for the
smyc DosR overlap
GTGCTTGTGGTGGCATC To sequence for DosR
C
promoter in pUAB 100
GCCGCCAGGAGCATT
To sequence for DosR
promoter in pUAB 200
GTGGTTGTGGTGATGTA To sequence for DosR
CGTG
promoter in pst5552
GATCGTCGGCACCGT
Forward primer at the start
of smyc promoter for
screening
CCGACAACGCAGACCGT To sequence promoter
driving GFP on PVVRG
GCATCACCTTCACCCTCT To sequence promoter
CC
driving GFP on PVVRG
GATCGTCGGCACCGT
Forward primer at the start
of smyc promoter for
screening
CAGTACGCGAAGAACCA To confirm smyc in pUAB200
CGC
by sequencing
GACATCTGGGCGCGC
To confirm smyc in pUAB200
by sequencing
GGAGCTCACCGCCAGAA To confirm smyc in pST5552
T
by sequencing
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